text
"[""\n3. 타법인출자 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2022년 12월 31일\n)\n(단위 : 백만원, 주, %)\n법인명\n상장여부\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\n씨씨알㈜\n비상장\n2005.01.02\n투자\n74\n13,489\n0.32\n-\n-\n-\n-\n13,489\n0.32\n-\n8,674\n75\n일성신약㈜\n상장\n2006.06.05\n투자\n930\n1,000\n0.04\n74\n-1,000\n-105\n31\n-\n-\n-\n371,383\n-1,368\n㈜퓨어스피어\xa0\n비상장\n2016.11.03\n투자\n300\n3,000\n6.52\n218\n-\n-\n-\n3,000\n6.52\n218\n11,686\n1,227\n프리미어 글로벌 이노베이션1호 투자조합\n비상장\n2017.06.15\n투자\n560\n-\n4.00\n2,663\n-\n-319\n-27\n-\n4.00\n2,317\n60,347\n12,429\n라이프코어-이앤 신기술 사업투자조합 1호\n비상장\n2017.08.10\n투자\n500\n-\n12.20\n500\n-\n-\n-\n-\n-\n500\n3,805\n-106\n㈜클리노믹스\n상장\n2018.07.20\n투자\n1,000\n138,928\n1.04\n1,799\n-\n-\n-879\n138,928\n1.04\n920\n102,587\n15,853\n㈜티움바이오\n상장\n2019.04.30\n투자\n3,000\n125,000\n0.53\n2,413\n-\n-\n-838\n125,000\n0.53\n1,575\n113,722\n-32,253\n시너지 바이오 헬스케어 벤처펀드\n비상장\n2019.05.16\n투자\n601\n-\n-\n1,768\n-\n-\n-\n-\n-\n1,768\n24,694\n-504\n보고신기술사업금융전문투자형 사모투자신탁 제2호\n비상장\n2019.06.04\n투자\n1,000\n-\n-\n740\n-\n-\n-534\n-\n-\n206\n10,337\n-3,354\nDS Benefit,XV 전문투자형 사모투자신탁\n비상장\n2020.05.29\n투자\n300\n-\n-\n300\n-\n-\n-\n-\n-\n300\n4,509\n1\n수성코스닥벤처 M6 전문투자형 사모투자신탁\n비상장\n2020.10.16\n투자\n2,000\n-\n-\n2,379\n-\n-\n-97\n-\n-\n2,282\n30,025\n1,819\n프리미어 글로벌 이노베이션 2호 투자조합\n비상장\n2020.11.03\n투자\n250\n-\n-\n2,408\n-\n1,185\n-121\n-\n-\n3,472\n43,638\n-1,919\n㈜엘베이스\n비상장\n2020.12.28\n투자\n2,000\n93,053\n5.97\n2,000\n-\n-\n-\n93,053\n5.97\n2,000\n5,372\n-2,182\n엠투엔 제14회차 사모 전환사채\n비상장\n2021.06.28\n투자\n1,017\n-\n-\n1,017\n-\n-1,017\n-\n-\n-\n-\n197,826\n-58,123\n신보2021제14차유동화전문회사 제1-3회 무보증후순위공모사채\n비상장\n2021.08.27\n투자\n270\n-\n-\n270\n-\n-\n-\n-\n-\n270\n-\n-\nNH 앱솔루트 코스닥벤처 메자닌 1호\n비상장\n2021.09.23\n투자\n2,000\n-\n-\n1,951\n-\n-\n-85\n-\n-\n1,865\n60,921\n76\n더블유피 기술혁신 스타트업 2호조합\n비상장\n2021.11.19\n투자\n200\n-\n-\n200\n-\n150\n-\n-\n-\n350\n764\n-3\n디지털 이노베이션 벤처투자조합\n비상장\n2021.12.16\n투자\n3,000\n-\n29.24\n3,000\n-\n-\n-\n-\n29.24\n3,000\n10,254\n-6\nList Biotherapeutics, Inc.\n비상장\n2022.01.14\n투자\n3,570\n-\n-\n-\n-\n3,570\n-\n-\n-\n3,570\n27,717\n-\n수성프로젝트 T1 일반 사모투자신탁\n비상장\n2022.01.26\n투자\n2,000\n-\n-\n-\n-\n2,000\n-\n-\n-\n2,000\n-\n-\n글라세움 우선주\n비상장\n2022.04.01\n투자\n3,000\n-\n-\n-\n-\n3,000\n8\n-\n-\n3,008\n25,634\n-8,214\n한국제약협동조합\n비상장\n1978.04.04\n공동출자\n162\n663\n6.26\n162\n-\n-\n-\n663\n6.26\n162\n12,090\n5\n대원메디테크㈜\n비상장\n2011.04.12\n경영참여\n2,300\n2,799,999\n64.42\n-\n-\n-\n-\n2,799,999\n64.42\n-\n2,463\n-1,032\n㈜다나젠\n비상장\n2015.12.11\n경영참여\n40\n679,184\n28.60\n1,040\n-24,000\n-37\n-\n655,184\n27.58\n1,003\n9,187\n1,760\nDAEWON PHARMACEUTICAL(Vietnam) Co., Ltd.\n비상장\n2017.07.31\n경영참여\n430\n-\n100.00\n836\n-\n-\n-\n-\n100.00\n836\n477\n-311\n극동에치팜㈜\n비상장\n2021.05.26\n경영참여\n14,114\n60,553\n83.53\n14,602\n-\n-\n-2,208\n60,553\n83.53\n12,394\n27,118\n-355\n합 계\n3,914,869\n-\n40,340\n-25,000\n8,427\n-4,750\n3,889,869\n-\n44,016\n-\n-\n주1) 상기표 '최근사업연도 재무현황'은 2021년도(말) 기준입니다. 주2) '수성프로젝트 T1 일반 사모투자신탁'의 경우 2022년도 출시 상품으로 최근 사업연도 재무현황 기재 생략하였습니다.\xa0\n""]"
